Glox Therapeutics has been awarded a share of the £3 ($3.6) million funding from the Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc. Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development… Read More
Glox Therapeutics has secured £1 million in grant funding from Pathways to Antimicrobial Clinical Efficacy (PACE), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery. The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic… Read More
Glox Therapeutics has raised £4.3M ($5.2M) in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. Glox Therapeutics is developing… Read More
